Shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) have earned a consensus rating of “Buy” from the six analysts that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $18.30.

A number of research firms recently commented on GLMD. Roth Capital began coverage on shares of Galmed Pharmaceuticals in a research note on Wednesday. They issued a “buy” rating and a $32.00 target price for the company. Zacks Investment Research upgraded shares of Galmed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.50 target price for the company in a research note on Tuesday. HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of Galmed Pharmaceuticals in a research note on Friday, November 10th. Maxim Group reiterated a “buy” rating and issued a $14.00 target price on shares of Galmed Pharmaceuticals in a research note on Thursday, November 9th. Finally, Seaport Global Securities reiterated a “buy” rating and issued a $19.00 target price on shares of Galmed Pharmaceuticals in a research note on Friday, October 6th.

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. KCG Holdings Inc. bought a new stake in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 20,473 shares of the biopharmaceutical company’s stock, valued at approximately $100,000. KCG Holdings Inc. owned approximately 0.17% of Galmed Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 8.25% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Galmed Pharmaceuticals Ltd. (GLMD) Given Average Recommendation of “Buy” by Analysts” was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/11/15/galmed-pharmaceuticals-ltd-glmd-given-average-recommendation-of-buy-by-analysts.html.

Galmed Pharmaceuticals (NASDAQ GLMD) traded down $0.22 during mid-day trading on Wednesday, reaching $7.38. 32,800 shares of the company were exchanged, compared to its average volume of 35,245. Galmed Pharmaceuticals has a one year low of $3.04 and a one year high of $9.59.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.

Receive News & Ratings for Galmed Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.